William Blair downgraded Eyenovia (EYEN) to Market Perform from Outperform after the review of the CHAPERONE trial data by an independent Data Review Committee found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio